GlassScriptPhysician profile
Hafiz M Imran
NPI 1962705590
$17,984.59
in general payments reported to CMS, 2019-2025
30 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $84.99 · 2021: $148 · 2022: $1,206 · 2023: $11K · 2024: $2,960 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $11K · Food and Beverage: $3,144 · Travel and Lodging: $2,728 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,500.00 |
| Food and Beverage | $3,143.75 |
| Travel and Lodging | $2,728.29 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,179.45 | 2023-2024 | Corevalve Evolut R |
| Abbott Laboratories | $5,190.19 | 2022-2024 | Mitraclip |
| Edwards Lifesciences Corporation | $3,726.00 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $372.44 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $214.47 | 2024-2025 | |
| Bridgebio Pharma, INC. | $169.19 | 2025 | Attruby |
| Pfizer INC. | $168.24 | 2024-2025 | |
| Amgen INC. | $150.08 | 2024-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $148.00 | 2022 | |
| Penumbra, INC. | $139.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.33 | 2024-2025 | Jardiance |
| Teleflex LLC | $129.51 | 2023 | Manta |
| Actelion Pharmaceuticals US, INC. | $123.64 | 2022-2025 | Opsumit |
| Scpharmaceuticals INC. | $122.58 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $100.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $93.20 | 2024-2025 | Onpattro, Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $85.01 | 2024 | Arcalyst |
| Novo Nordisk INC | $79.08 | 2025 | Wegovy |
| Abiomed | $64.77 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.92 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.72 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $43.42 | 2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $42.54 | 2025 | Lokelma |
| Harmony Biosciences LLC | $29.06 | 2024 | |
| Cardiva Medical, INC. | $27.74 | 2024 | Optowire |
| Philips North America LLC | $25.59 | 2025 | Igt Devices Undivided |
| Janssen Pharmaceuticals, INC | $23.13 | 2024 | Xarelto |
| Lilly USA, LLC | $22.82 | 2025 | Zepbound |
| Esperion Therapeutics, INC. | $20.57 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hafiz Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.